Alzheimer’s Disease Tau Consortium: Strain Replication in Mouse and Cell Models
|
Marc Diamond
|
2024-12-27
|
Alzheimer’s Disease Tau Consortium: Toxic Consequences of Early Tau Seeding
|
Bradley T. Hyman
Rachel Bennett
|
2024-12-24
|
Alzheimer’s Disease Tau Consortium: The Role of Amyloid Beta-Induced Membrane Damage in Tau Pathology
|
Katherine Sadleir
Robert Vassar
|
2024-12-23
|
Alzheimer’s Disease Tau Consortium: Post-Translational Modifications and Tau Ultrastructure; Impact of Amyloid Beta on Tau In Vivo
|
Karen Duff
René Frank
|
2024-12-23
|
Protection Against Alzheimer’s Disease with Longevity-Promoting Intervention 17a-Estradiol
|
Christian Pike
Bérénice A. Benayoun
|
2024-12-23
|
Plasma Proteins, Sex and Alzheimer’s Disease: Proteome-Wide Analyses of the UK Biobank and Framingham Heart Study
|
P. Murali Doraiswamy
|
2024-12-16
|
APOE in Choroid Plexus Function and Related Alzheimer’s Disease Pathogenesis
|
Guojun Bu
|
2024-12-16
|
Relationship Between Alzheimer’s Disease Risk Score and Outcomes of Mild Repetitive Neurotrauma
|
Thomas McAllister
Michael McCrea
|
2024-12-16
|
Alzheimer’s Disease PET Imaging of Nonfibrillar Amyloid Beta Aggregates Using Azapeptide (AZP) Tracer
|
Sam Gandy
Brigitte Guérin Shai Rahimipour William Lubell
|
2024-12-16
|
Identifying Age-Related Proteomic Changes That Predict Future Onset of Amyloid Beta Aggregation in Late-Onset Alzheimer’s Disease
|
Randall J. Bateman
|
2024-12-16
|
Investigating the Serial Pathologies Related to Plasma Biomarkers in NLFTaum/h Mice: A New Mouse Model Featuring Neurofibrillary Tangles as a Result of Rising Amyloid Beta without Microtubule-Associated Protein Tau (MAPT) Mutations
|
Frances Edwards
John Hardy
|
2024-12-16
|
Sex-Biased Toll-Like Receptor 7 (TLR7) Signaling in Demyelination and Its Inhibition by Small Molecules
|
Li Gan
Subhash Sinha
|
2024-11-23
|
Selective Vulnerability in Posterior Cortical Atrophy
|
John R. Dickson
Bradley T. Hyman
|
2024-11-21
|
APOE Consortium: APOE4 Accelerates CD8 Exhaustion via Glucocorticoid Signaling in Alzheimer’s Female Carriers
|
Oleg Butovsky
Vijay K. Kuchroo
|
2024-11-20
|
APOE Consortium: Cell Autonomous Roles of Protective APOE Variants in Microglia in Response to Amyloid Pathology
|
Michael Haney
|
2024-11-20
|
APOE Consortium: Investigating Potential Cell Autonomous Neuroprotection of APOE Protective Variants
|
David Holtzman
|
2024-11-20
|
Integrating Single-Cell Genomics for Pathways to Protection and Resilience Against Alzheimer’s Disease
|
Winston Hide
|
2024-10-31
|
Probing the Molecular Underpinnings of G Protein-Coupled Receptor ADGRG1 Mediated Protective Microglial Responses to Alzheimer’s disease
|
Xianhua Piao
|
2024-10-31
|
Evaluating the Contribution of TDP-43 Dysfunction and Cryptic Mis-Splicing to Alzheimer’s Disease Pathogenesis
|
Leonard Petrucelli
|
2024-10-31
|
Multidimensional Profiling of TREM2-Mutated or APOE4-mutated Microglia in Human Brain Organoids to Understand Dysregulated Microglia Neuronal Crosstalk in Alzheimer’s Disease
|
Florent Ginhoux
|
2024-10-31
|
Midlife Autoantibody Profiles and the Risk of Late-Onset Alzheimer’s Disease in Women
|
Yu Chen
|
2024-10-31
|
Role of Psychosocial Stress in Alzheimer’s Disease
|
Filip Swirski
|
2024-10-31
|
Impact of DNA Damage-Mediated Stimulator of Interferon Genes (STING) Activation on Myelin Function in an Alzheimer’s Disease Animal Model
|
Alban Gaultier
|
2024-09-24
|
Pre-Clinical Testing of CDK4/6 Inhibitors as a Therapeutic Strategy in Alzheimer’s Disease Using Alzheimer’s Disease Tauopathy Mouse Model
|
Peter Sicinski
|
2024-09-24
|
Mapping the X Chromosome Multi-Ome in Alzheimer’s and Parkinson’s Disease
|
Michael Belloy
|
2024-09-17
|
Targeting Reactive Astrocytes AMPK Signaling to Suppress Inflammation in Alzheimer’s Disease
|
Gilbert Gallardo
|
2024-09-16
|
Contributions of IL34 Signaling to Microglial Function and Alzheimer’s Pathology in Mice
|
Staci Bilbo
|
2024-09-16
|
Bioinformatics Platform for Modeling Alzheimer’s Progression (MAP-AD Platform)
|
Ali Ezzati
|
2024-09-16
|
Meningeal Regulatory T Cells (Tregs) in Individuals With Versus Without Alzheimer’s Disease
|
Diane Mathis
|
2024-09-16
|
Elucidating Mechanisms Driving the Compromised Balance Between Mitophagy and cGAS-STING-Initiated Inflammation Toward a Treatment for Alzheimer’s Disease
|
Per Nilsson
Evandro F. Fang
|
2024-08-22
|
Understanding Human Brain Resilience to Alzheimer’s Pathology
|
Teresa Gomez-Isla
|
2024-08-19
|
Combined Hormone Therapy as a Novel Treatment for Alzheimer’s Disease in the Face of a Metabolic Challenge: Influence of Sex and Genotype
|
Liisa Galea
Annie Ciernia
|
2024-08-19
|
Dysregulation of Signaling on Post Synaptic Density Scaffolds in Alzheimer’s Disease
|
Alexandra C. Newton
|
2024-07-29
|
Novel Artificial Intelligence (AI) Decodes Aging Neurons
|
Andrew J. Holbrook
Theodore Zwang
|
2024-07-23
|
2-Deoxyglucose and Its Analogs as Novel Therapeutics to Build Resilience to Alzheimer’s Disease
|
Rajiv R. Ratan
Theodore J. Lampidis
|
2024-07-23
|
2024 Jeffrey L. Morby Prize for Exceptional Research
|
David Holtzman
|
2024-07-03
|
Hypertension, Tau and Neurodegeneration
|
Costantino Iadecola
Giuseppe Faraco
|
2024-06-28
|
Non-Invasive Delivery of IL-2 to the CNS for Local Expansion of Regulatory T Cells and Prevention of Neurodegeneration in Tauopathy
|
Peter M. Tessier
David Holtzman
|
2024-06-26
|
Circuit Dynamics in APOE4 Mice
|
Ksenia Kastanenka
|
2024-06-17
|
The Role of Calcium Homeostasis in Axonal Spheroid Formation in Alzheimer’s Disease
|
Jaime Grutzendler
|
2024-06-13
|
Investigating Alzheimer’s Disease-Associated Membrane Biology in Microglia and Neurons
|
Anna Greka
Beth Stevens
|
2024-05-31
|
Modulating the Levels of Tau-Seed Interactors to Treat Alzheimer’s Disease
|
Cristian Lasagna-Reeves
|
2024-05-29
|
Dissecting Microglial State Dynamics in Alzheimer’s Disease
|
Li-Huei Tsai
|
2024-05-02
|
Brain Entry and Exit Consortium: Neuroinflammation at the Choroid Plexus in Alzheimer’s Disease
|
Maria Lehtinen
|
2024-05-02
|
Brain Entry and Exit Consortium: Does Subarachnoid Lymphatic-Like Membrane (SLYM) Failure Compromise Glymphatic Clearance in Alzheimer’s Disease?
|
Maiken Nedergaard
|
2024-05-02
|
Brain Entry and Exit Consortium: High-Resolution Magnetic Resonance Imaging of the Brain Borders
|
Daniel S. Reich
|
2024-05-02
|
Brain Exit and Entry Consortium: Human Three-Dimensional Neurovascular Interaction and Meningeal Lymphatics Models with Application to Alzheimer’s Disease
|
Se Hoon Choi
|
2024-05-02
|
Brain Entry and Exit Consortium: How Does Vascular Fatty Acid Metabolism Regulate the Pathophysiology of Alzheimer’s Disease?
|
Richard Daneman
|
2024-05-01
|
Brain Entry and Exit Consortium: Meningeal Mast Cell Control of Cerebrospinal Fluid Dynamics in Homeostasis and Alzheimer’s Disease
|
Jonathan Kipnis
|
2024-04-30
|
The Role of Astrocyte-Secreted Insulin-Like Growth Factor Binding Protein 2 (IGFBP2) in the Progression of Alzheimer’s Disease
|
Nicola Allen
|
2024-04-09
|
Specificity of T-Cell Responses in Autosomal Dominant Alzheimer’s Disease (ADAD)
|
Naresha Saligrama
|
2024-03-19
|
Neuroimmune Consortium: Astrocyte Inflammatory Contributions to Alzheimer’s Disease
|
Shane Liddelow
|
2024-03-18
|
Cellular Vulnerability to Pathological Tau Protein Accumulation in Alzheimer’s Disease
|
Mathieu Bourdenx
Karen Duff
|
2024-03-18
|
Preclinical Analysis of Synaptogyrin-3 Oligonucleotides to Target Tauopathy
|
Patrik Verstreken
|
2024-03-18
|
Tau and Amyloid Beta are Innate Immune Antimicrobial Peptides in the Brain
|
William Eimer
|
2024-02-29
|
Decipher the Astrocyte Cell-Surface Proteome in Alzheimer’s Disease
|
Hui Zheng
Junmin Peng
|
2024-02-28
|
Elucidating the Therapeutic Potential of the Endo-Lysosome Pathway for Alzheimer’s Disease
|
Jessica Young
|
2024-02-28
|
T-Cell Modulation of Microglia to Treat Alzheimer’s Disease
|
Howard L. Weiner
|
2024-02-28
|
Investigating the Association Between Clonal Hematopoiesis and Alzheimer’s Disease
|
Cameron McAlpine
|
2024-02-28
|
Multiomic and Functional Characterization of Soluble TREM2 Modifiers
|
Carlos Cruchaga
|
2024-02-28
|
Systematic Assessment of Tandem Repeats in Alzheimer’s Disease (STaR-AD)
|
Lars Bertram
Valerija Dobricic
|
2024-02-28
|
General Scientific Support
|
Wilma Wasco
|
2024-02-06
|
Defining a Role for the MS4A Genes in Alzheimer’s Disease
|
Sandeep Robert Datta
|
2024-02-01
|
Neuroimmune Consortium: Impact of AD Polygenic Risk Score on Microglial Response to Peripheral Inflammation
|
Martine Therrien
|
2024-02-01
|
ADAM10 Cleavage of Amyloid Precursor Protein: Physiological Function in the Brain and Therapeutic Potential for Alzheimer’s Disease
|
Jaehong Suh, Ph.D.
|
2024-02-01
|
Interpreting Alzheimer’s Disease-Associated Genetic Variation at Enhancer Regions
|
Andreas R. Pfenning
|
2024-02-01
|
Moving the Cure Alzheimer’s Fund Alzheimer’s Genome Project™ Beyond Simple Associations: Integrating Functional Information, Fine-Mapping and Causal Inference Approaches into the Family-Based Analysis of the Cure Alzheimer’s Fund Whole-Genome Sequencing (WGS) Family Study
|
Christoph Lange
|
2024-02-01
|
Do Classical Complement Activation and the Route of Administration of Anti-Amyloid Antibodies Contribute to Vascular Side Effects Known as Amyloid-Related Imaging Abnormalities?
|
Cynthia A. Lemere
|
2024-02-01
|
Exploring Novel Drug Candidates for Alzheimer’s Disease Through Integrative Pathway Analysis and Validation in 3D Cellular Models
|
Doo Yeon Kim
Luisa Quinti
|
2024-02-01
|
Development of Small Molecule Inhibitors of Cholesterol 25-hydroxylase
|
Anil Cashikar
Bahaa Elgendy
|
2024-02-01
|
Characterization and Validation of Two Recently Created Sheep Models of Alzheimer’s Disease in Preparation for Use as a Preclinical Pharmaceutical Testing Model
|
Russell G. Snell
Natasha McKean
|
2024-01-31
|
A New Model of Microglia Genetic Perturbation in Vivo to Screen All Risk Factors Associated with Alzheimer’s Disease
|
Oleg Butovsky
Vijay K. Kuchroo
|
2024-01-12
|
Investigating the Role of Tau Protein in Neuronal Senescence
|
Miranda Orr
|
2024-01-12
|
Deciphering and Restoring Computational Setpoints in Alzheimer’s Disease Through Sleep-Enhanced Network Homeostasis
|
Keith Hengen
|
2024-01-12
|
Utility of Blood-Based Markers for Predicting Amyloid-Related Imaging Abnormalities and Their Course in Mild Cognitive Impairment and Alzheimer’s Disease Subjects Undergoing Routine Clinical Treatment with Amyloid-Directed Antibodies
|
P. Murali Doraiswamy
|
2024-01-12
|
Understanding the Dynamic Lipid-Immunometabolome of Protective and Risk Alzheimer’s Microglia
|
Rik van der Kant
|
2024-01-12
|
Neuroimmune Consortium: Mechanisms Mediating Microglia Sensing of Peripheral Inflammation
|
Christopher K. Glass
|
2024-01-11
|
Neuroimmune Consortium: Effects of Peripheral Inflammation on Myeloid Cell Function in Alzheimer’s Disease
|
Beth Stevens
|
2024-01-11
|
Extracellular ATP is a Key Factor in Promoting Alzheimer’s Disease Neuroinflammation
|
Paola Pizzo
Anna Lisa Giuliani Francesco Di Virgilio
|
2024-01-11
|
Neuroimmune Consortium: Examining the Impact of Peripherally Derived Human Macrophages in Alzheimer’s Disease Pathogenesis
|
Mathew Blurton-Jones
|
2024-01-11
|
Investigating MEF2C Transcription Factor as a Therapeutic Target to Reprogram Pathological Microglial States in Alzheimer’s Disease
|
Alison Goate
Edoardo Marcora
|
2024-01-11
|
Morphological, Electrophysiological and Transcriptional Characterization of Single Neurons from Resilient and Susceptible Models of Human Alzheimer’s Disease
|
Catherine Kaczorowski
Shannon Moore
|
2024-01-10
|
Neuronal Mechanisms Driving Synapse Loss in Alzheimer’s Disease
|
Martin Kampmann
|
2024-01-10
|
A Multimodality Study on the Lipid Molecular Basis of Obesity and Its Roles in Regulating Alzheimer’s Pathogenesis for Developing Potential Targeted Interventions
|
Stephen T.C. Wong
|
2024-01-10
|
Role of Checkpoint Molecules TIM-3 and LAG-3 in Microglial Function in Alzheimer’s Disease
|
Vijay K. Kuchroo
|
2023-12-21
|
To Elucidate the Role of Memory T Cells as a Determinant of Age-Related Inflammation in Alzheimer’s Disease
|
Susan M. Kaech
|
2023-12-21
|
Neuroproteasomes Mechanistically Connect APOE Isoforms to Endogenous Tau Aggregation
|
Kapil V. Ramachandran
|
2023-12-21
|
APP Gene Dose-Mediated Dysregulation of the Endolysosomal Network Acts to Compromise Synaptic Structure and Function Leading to Alzheimer’s Disease in Down Syndrome
|
William C. Mobley
|
2023-12-21
|
The Role of Interferon-Induced Transmembrane Protein 3 (IFITM3) and Gamma-Secretase in Microglia
|
Yueming Li
|
2023-12-21
|
Neuroinflammation at the Choroid Plexus in Alzheimer’s Disease
|
Maria Lehtinen
Liisa Myllykangas
|
2023-12-21
|
Investigating Lysosomal Mechanisms of Risk and Resilience in Alzheimer’s Disease
|
Joel Blanchard
|
2023-12-09
|
Multiomics Characterization of Tau Pathology Onset and Its Relationship with Amyloid in the Human Hippocampus
|
Inma Cobos
|
2023-12-09
|
Restore Meningeal Lymphatic Drainage to Alleviate White Matter Damage and Cerebral Amyloid Angiopathy in a Model of Alzheimer’s Disease
|
Sandro Da Mesquita
|
2023-12-09
|
Circadian Desynchrony, Glial Dysfunction and Alzheimer’s Disease Pathogenesis
|
Erik S. Musiek
|
2023-12-09
|
Contribution of Skull Bone Marrow-Derived Cells to Alzheimer’s Disease
|
Jonathan Kipnis
|
2023-12-08
|
Oligodendroglial Dynamics and Myelination in Alzheimer’s Disease
|
Erin M. Gibson
|
2023-12-08
|
Identifying Mediators of Tau-Mediated Neuronal Necroptosis Using an Innovative In Vivo CRISPR Screen
|
Bart De Strooper
Sriram Balusu
|
2023-12-08
|
Scaling the Divide in Alzheimer’s Disease: An Integrated Molecular, Cellular and Network-Level Study
|
Marc Aurel Busche
Samuel Harris
|
2023-12-08
|
Mechanisms of Astrocyte-Derived Lipid Toxicity in Alzheimer’s Disease
|
Shane Liddelow
|
2023-12-08
|
Noncoding Translation Feedback Loop in Alzheimer’s Disease
|
Xuebing Wu
|
2023-12-08
|
Growth, Characterization and Distribution of a Neurodegenerative Disease-Focused Fibroblast/iPS Cell Bank to Support Molecular Models of Patient-Specific Variation with Validation in Matched Donated Brain Tissues
|
Derek H. Oakley
|
2023-12-08
|
Microbiome Consortium: Interaction of the Microbiome with Astrocytes and Amyloid Pathology
|
Robert Vassar
|
2023-11-02
|
Microbiome Consortium: Microbial Profiling of Human Brain and Gut Microbiomes in Alzheimer’s Disease
|
Rudy Tanzi
Nanda Kumar Navalpur Shanmugam
|
2023-11-02
|
Microbiome Consortium: Temporal Relationships Between Gut Dysbiosis, Brain Amyloid Beta Metabolism and Microglia Cell Activation Following Antibiotic Treatment
|
Sangram S. Sisodia
|
2023-11-02
|
Microbiome Consortium: The Role of Gut Microbial Metabolism in Tau-Mediated Neurodegeneration
|
David Holtzman
|
2023-11-02
|
Microbiome Consortium: Harnessing Diet-Microbe Interactions to Prevent Alzheimer’s Disease Pathogenesis
|
Laura Cox
|
2023-11-02
|
Elucidating the Protective Effects of APOE2 in the Presence of APOE4 Gene Allele in Animal Models
|
Na Zhao
Yingxue Ren
|
2023-11-02
|
Role of Stabilization of MAMs and MAM-Associated Palmitoylated APP (MAM-palAPP) in Alzheimer’s Disease
|
Raja Bhattacharyya
|
2023-11-02
|
Mitochondrial Alzheimer’s Risk Factors Control APOE Expression and Secretion
|
Victor Faundez
|
2023-10-26
|
Targeting Neuroinflammation with Nasal Administration of Anti-CD3 Monoclonal Antibody to Treat Alzheimer’s Disease
|
Rafael M. Rezende
|
2023-10-25
|
Multidisciplinary Phenotyping of a Novel Humanized LOAD Mouse Model
|
Giuseppina Tesco
|
2023-10-25
|
Elucidating the Role of CLEC7A in Tau-Mediated Neurodegenerative Disease
|
John R. Lukens
|
2023-10-25
|
Validation and Characterization of Compounds Modulating Neuroinflammation and Amyloid Beta Uptake in Microglial Cells
|
Ana Griciuc
Luisa Quinti
|
2023-10-25
|
Identification and Development of CD33 Inhibitors and Pre-RNA Splicing Modulators
|
Subhash Sinha
|
2023-10-25
|
Dissecting Alzheimer’s Disease Phenotypes in Directly Reprogrammed Patient-Derived Neurons
|
Andrew S. Yoo
|
2023-10-25
|
Neuroprotective Effects of the Exercise Hormone Irisin in Alzheimer’s Disease
|
Se Hoon Choi
Christiane Wrann
|
2023-10-25
|
Tau-Induced Postsynaptic Dysfunction in Tauopathy Models
|
Karin Hochrainer
Costantino Iadecola
|
2023-09-19
|
Role of CD8+ T Cell–Glial Interactions in Mediating Alzheimer’s Disease Pathogenesis
|
Mehdi Jorfi
Joseph Park Rudy Tanzi
|
2023-09-19
|
Characterization of the Longitudinal Trajectories of the Synaptic Blood Marker Beta-Synuclein During Alzheimer’s Disease Pathogenesis and Improvement of the Measurement Procedure
|
Patrick Oeckl
Markus Otto
|
2023-09-19
|
Endogenous Human Antibodies Associated with Alzheimer’s Disease
|
Charles Glabe
|
2023-09-19
|
In Vivo Models for Golgi Fragmentation and the Molecular Pathogenesis of Alzheimer’s Disease
|
Sam Gandy
Yanzhuang Wang
|
2023-09-19
|
Functional Changes to Cerebrospinal Fluid Immune Cells Resulting from Bacillus Calmette-Guérin (BCG) Vaccination in Older Adults With and Without Alzheimer’s Disease
|
Marc Weinberg
Steven Arnold
|
2023-07-11
|
Role of Ras and Rab Interactor 3 (RIN3) and Bridging Integrator 1(BIN1) Interaction in the Neurons for Alzheimer’s Disease Development
|
Raja Bhattacharyya
|
2023-07-10
|
Characterizing Gut Bacteriome-Mycobiome Synergy in Correlation to Amylin-Amyloid Beta Antimicrobial Synergy in Alzheimer’s Disease (AD) in AD Mouse Models
|
Deepak Kumar Vijaya Kumar
|
2023-05-02
|
Decoding Microbial Products Modulating Alzheimer’s Disease—Toward Precision Postbiotics Treatment
|
Eran Elinav
|
2023-05-02
|
CIRCUITS: Dissecting Microglial State Dynamics in Alzheimer’s Disease
|
Li-Huei Tsai
|
2023-05-02
|
Brain Entry and Exit Consortium: A 3D In Vitro Neurovascular Human Brain Model with Meningeal Lymphatics for Elucidating Mechanisms Underlying Alzheimer’s Disease
|
Se Hoon Choi
|
2023-05-02
|
Genomic Variant Calling and Data Management for the Cure Alzheimer’s Fund Alzheimer’s Genome Project™
|
Winston Hide
|
2023-05-02
|
Precision Medicine Prediction Model for Alzheimer’s Disease Using Cooperative Learning Approaches for Multi-Omic Data
|
Christoph Lange
|
2023-05-02
|
Antiviral T-Cell Infiltration to the Meninges and Brain Influences Neurodegeneration in Alzheimer’s Disease
|
Jasmin Herz
|
2023-03-23
|
Characterization of CNS-Penetrant HDAC11-Selective Inhibitors in Alzheimer’s Disease Models
|
Can (Martin) Zhang
Changning Wang
|
2023-03-21
|
Genetic Ancestry-Specific Risk Estimation of Alzheimer’s Disease in the APOE Region
|
Christoph Lange
|
2023-03-21
|
Effect of APOE Genotype in a Novel Rat Model of Cerebral Amyloid Angiopathy
|
William Van Nostrand
|
2023-03-21
|
Analytical and Statistical Tools for Sequence Analysis for Alzheimer’s Disease
|
Christoph Lange
|
2023-02-28
|
Adding Genomics and Methylomics to Personalized Disease Prediction for Alzheimer’s Disease (EPIC4AD)
|
Lars Bertram
Christina M. Lill
|
2023-02-28
|
Identification and Validation of Plasma-Based Lipid Biomarkers for Early Alzheimer’s Disease in the Unique, Primarily Hispanic, South Texas Population
|
Xianlin Han
Bernard Fongang Juan Pablo Palavicini Tiffany F. Kautz
|
2023-02-23
|
A Proposal to Evaluate the Effect of Bacillus Calmette-Guérin Vaccination on Alzheimer’s Disease Development
|
Tamir Ben-Hur
Herve Bercovier
|
2023-02-23
|
The Impact of Mutations in the Ligand-Binding Domain of CD33 on Alzheimer’s Disease Pathogenesis
|
Ana Griciuc
|
2023-02-22
|
Structural Mimicry in Microbial and Antimicrobial Amyloids Connected to Neurodegenerative Diseases
|
Meytal Landau
|
2023-01-20
|
Alzheimer’s Disease Tau Consortium: Role of VCP/p97 in Tau Prion Replication
|
Marc Diamond
|
2023-01-20
|
Alzheimer’s Disease Tau Consortium: The Role of Amyloid Beta-Induced Membrane Damage in Tau Pathology
|
Katherine Sadleir
Robert Vassar
|
2023-01-18
|
Alzheimer’s Disease Tau Consortium: How Do Soluble Tau Species Replicate
|
Bradley T. Hyman
|
2023-01-18
|
Alzheimer’s Disease Tau Consortium: Impact of Tau Mutations and Amyloid Beta on Tau Post-Translational Modifications and Conformation
|
Karen Duff
|
2023-01-18
|
RNA as a Determinant of Tau Seeding
|
Marc Diamond
|
2023-01-12
|
Alzheimer’s Disease Tau Consortium: Deep Mass Spectrometry Profiling of Tau Aggregates in Alzheimer’s Disease and Other Tauopathies
|
Henrik Zetterberg
Gunnar Brinkmalm
|
2023-01-06
|
Genes to Therapies (G2T), Alzheimer’s Disease Drug Discovery & Development (AD4) and General Scientific Support
|
Wilma Wasco
|
2023-01-06
|
Role of the Circulating Exerkine GPLD1 in Ameliorating Alzheimer’s Disease Pathology
|
Saul Villeda
|
2023-01-06
|
Using Long-Read Sequencing to Investigate the MAPT Locus and Transcripts in Neurodegeneration
|
John Hardy
|
2023-01-06
|
Alzheimer’s Disease Pathophysiology Alters the Level of Electrical and Chemical Synapse Coupling in the Network of GABAergic PV+ Interneurons Early in Disease Course
|
Srdjan D. Antic
Riqiang Yan
|
2023-01-05
|
Identifying the Sex-Specific Roles of the Gut Microbiome-Brain Axis in a Mouse Model of Amyloid Beta Amyloidosis
|
Sangram S. Sisodia
|
2022-12-22
|
Dissecting the Modulatory Roles of Interleukin-17 Receptor D in Alzheimer’s Disease
|
Jun Huh
|
2022-12-22
|
Toxic Effects of Extracellular Tau Oligomers on Neurons
|
George S. Bloom
|
2022-12-22
|
Fleming APOE Consortium: Modulation of Selective Neuronal Vulnerability in Alzheimer’s Disease by Apolipoprotein E
|
Jean-Pierre Roussarie
|
2022-12-22
|
Cerebrospinal Fluid Neuroinflammatory Signature in Alzheimer´s Disease and Related Proteopathies
|
Mathias Jucker
Stefan Lichtenthaler Stephan Kaeser
|
2022-11-22
|
Turning Up Mitophagy to Blunt Alzheimer’s Tau Pathologies
|
Evandro F. Fang
|
2022-11-21
|
Prenatal Inflammation Effects on Blood-Brain Barrier Function and Alzheimer’s Disease-Related Pathologies Across the Lifespan
|
Alexandre Bonnin
|
2022-11-21
|
Neuroimmune Consortium: Biomarker Tool Development
|
Jacob Hooker
|
2022-11-16
|
Understanding How Human Brain Vascular Cells Mediate Genetic Risk for Alzheimer’s Disease
|
Andrew Yang
|
2022-11-16
|
Microglial-Specific INPP5D Knockdown Modulates Behavior, Amyloidosis and Tauopathy in Alzheimer’s Mouse Models
|
Sam Gandy
Michelle E. Ehrlich
|
2022-11-16
|
Neuroimmune Connectome Perturbations in Alzheimer’s Disease
|
Francisco J. Quintana
|
2022-11-16
|
Fleming APOE Consortium: Effect of Cholesteryl Ester Transfer Protein Activity on Amyloid and Cerebrovascular Pathologies in Animal Models of Alzheimer’s Disease
|
Cheryl Wellington
|
2022-11-16
|
Fleming APOE Consortium: Role of APOE Isoforms in Immune Responses in a Model of Tauopathy
|
David Holtzman
|
2022-11-16
|
Fleming APOE Consortium: APOE4-Mediated Dysfunction of CD8 T Cell–Microglia Crosstalk in Alzheimer’s Disease
|
Oleg Butovsky
|
2022-11-16
|
Fleming APOE Consortium: APOE Genotype-Specific Effects of Human Young Plasma on Cerebrovasculature and Alzheimer’s Disease Pathology
|
Guojun Bu
|
2022-11-16
|
Neuroimmune Consortium: Assessing the Links Between the MS4A Risk Genes, Microglia and Alzheimer’s Disease
|
Sandeep Robert Datta
|
2022-08-15
|
Temporal Relationships Between Gut Dysbiosis and Microglia Cell Activation Following Antibiotic Treatment
|
Sangram S. Sisodia
|
2022-08-15
|
Evaluating TMEM106B Accumulation in Alzheimer’s Disease
|
Leonard Petrucelli
Casey Cook
|
2022-08-15
|
Exploring the Therapeutic Potential of Clusterin in a Preclinical Model of Alzheimer’s Disease
|
Alban Gaultier
|
2022-07-19
|
Cellular Vulnerability to Aging in Alzheimer’s Disease
|
Mathieu Bourdenx
Karen Duff
|
2022-07-19
|
Contributions of IL-34 Signaling to Microglial Function and Alzheimer’s Pathology in Mice
|
Staci Bilbo
|
2022-07-19
|
Targeting the Microbiome and Innate Immunity in Alzheimer’s Disease
|
Howard L. Weiner
Laura Cox
|
2022-06-23
|
Human Brain CD33 Ligand, Receptor Protein Tyrosine Phosphatase Zeta (RPTPζ)S3L, Limits Microglial Phagocytosis and Contributes to Alzheimer’s Disease Progression
|
Ronald Schnaar
Philip C. Wong
|
2022-06-23
|
Circadian Perturbations of the Vasculome and Microgliome in Alzheimer’s Disease
|
Eng H. Lo
|
2022-06-23
|
ABCA7 Loss of Function in Aging and Alzheimer’s Disease
|
Takahisa Kanekiyo
|
2022-06-23
|
Characterization of Tau Pathology Heterogeneity Across the Alzheimer’s Disease Spectrum
|
Oskar Hansson
Rik Ossenkoppele
|
2022-06-23
|
Neuroprotective Effects of the Exercise Hormone Irisin in Alzheimer’s Disease
|
Se Hoon Choi
Christiane Wrann
|
2022-06-23
|
Stress and Neurovascular-Immune Networks in Alzheimer’s Disease
|
Scott J. Russo
Wolfram C. Poller
|
2022-05-11
|
Regional Variability of Pathology-Associated Properties of Tau in Posterior Cortical Atrophy
|
Bradley T. Hyman
John R. Dickson
|
2022-05-09
|
Brain Entry and Exit Consortium: Central Nervous System Fluid Homeostasis and Waste Clearance in Alzheimer’s Disease Characterized by MRI
|
Helene Benveniste
Allen Tannenbaum David Xianfeng Gu
|
2022-05-09
|
Brain Entry and Exit Consortium: Identifying the Blood-Brain Barrier Changes During Alzheimer’s Disease
|
Richard Daneman
|
2022-05-05
|
Single Nucleus RNA Sequencing Analysis of ACE1 R1284Q Knock-in Mice
|
Robert Vassar
David M. Gate Leah Cuddy
|
2022-05-03
|
Brain Entry and Exit Consortium: Biochemical and Functional Analysis of Cerebrospinal Fluid and Lymph Following Changes in Brain Fluid Dynamics
|
Laura Santambrogio
|
2022-05-03
|
Brain Entry and Exit Consortium: Crosstalk of Central Nervous System Barriers and Clearance Routes in Homeostasis and Alzheimer’s Disease
|
Jonathan Kipnis
|
2022-05-03
|
Development of a Multicellular Brain Model to Study Brain-Vascular-Peripheral Immune Cells Crosstalk in Alzheimer’s Disease
|
Mehdi Jorfi
Joseph Park Rudy Tanzi
|
2022-02-17
|
CIRCUITS: Interpreting Alzheimer’s Disease-Associated Genetic Variation at Enhancer Regions
|
Andreas R. Pfenning
|
2022-02-17
|
Cellular and Molecular Studies of Apolipoprotein E Regulation of Blood-Brain Barrier, Synaptic and Neuronal Functions and Protection Strategies in Mouse Models With and Without Alzheimer’s Pathology
|
Berislav Zlokovic
|
2022-02-17
|
Elucidating the Role of Soluble Epoxide Hydrolase and Arachidonic Acid Metabolism in Neuroinflammation and Alzheimer’s Disease
|
Hui Zheng
|
2022-02-17
|
Neuronal Subtype-Specific Modeling of Alzheimer’s Disease by Direct Neuronal Reprogramming of Patient Fibroblasts
|
Andrew S. Yoo
|
2022-02-17
|
Alzheimer’s Disease Drug Discovery and Development Consortium: Blocking Synaptotoxicity in Alzheimer’s Three-Dimensional Models
|
Weiming Xia
|
2022-02-17
|
Alzheimer’s Disease Drug Discovery and Development Consortium: Uncovering the Molecular Mechanism of Selected Drug Candidates Derived from Systematic Alzheimer’s Drug Repositioning
|
Stephen T.C. Wong
|
2022-02-17
|
Genes to Therapies™ (G2T), Alzheimer’s Disease Drug Discovery & Development (AD4), ACTFAST and General Scientific Support
|
Wilma Wasco
|
2022-02-17
|
Continuing Studies of the Effects of GSM 776890 Administration on Amyloid Species and Microgliosis in Older Alzheimer’s Model Mice
|
Kevin Rynearson
|
2022-02-17
|
Targeting Tauopathies With Antisense Oligonucleotides to Synaptogyrin-3
|
Patrik Verstreken
|
2022-02-17
|
Neural Synaptic Circuit Changes During Alzheimer’s Disease Progression
|
Huizhong W. Tao
|
2022-02-17
|
Stimulating Synaptic Proteasome Activity for the Treatment of Alzheimer’s Disease
|
Hermann Steller
|
2022-02-15
|
Interrogating Levetiracetam’s Impact on Amyloid Pathology and Presynaptic Proteostasis in Knock-In Mouse Models with Humanized Amyloid Beta
|
Jeffrey Savas
|
2022-02-15
|
Brain Entry and Exit Consortium: Lymphatics and Central Nervous System Fluid Homeostasis
|
Laura Santambrogio
|
2022-02-15
|
Patient-Based Structural and Functional Biology of Tauopathies
|
Leonard Petrucelli
|
2022-02-15
|
Extracellular ATP Is a Key Factor in Promoting Alzheimer’s Disease Neuroinflammation
|
Paola Pizzo
Francesco Di Virgilio
|
2022-02-15
|
Protection Against APOE4 With Longevity-Promoting Interventions
|
Christian Pike
Bérénice A. Benayoun Caleb Finch
|
2022-02-15
|
Immunotherapies Targeting the Microbiota to Prevent Cognitive Decline in Alzheimer’s Disease
|
Gerald B. Pier
Colette Cywes-Bentley Cynthia A. Lemere
|
2022-02-15
|
Functional Basis for Novel Protein Kinase C-eta K56R Mutation in Alzheimer’s Disease
|
Alexandra C. Newton
|
2022-02-15
|
Investigating Bone Marrow Hematopoiesis as the Link Between Sleep Fragmentation and Vascular Inflammation in AD
|
Cameron McAlpine
Filip Swirski
|
2022-02-15
|
Role of Microglia in Degradation and Trimming of Alzheimer’s Amyloid Beta
|
Frederick Maxfield
|
2022-02-15
|
Targeting a Master Innate Immune Adaptor Molecule in Alzheimer’s Disease
|
John R. Lukens
|
2022-02-15
|
The Role of Astrocyte-Derived Toxic Lipids Mediating Degeneration in Alzheimer’s Disease
|
Shane Liddelow
|
2022-02-15
|
The Role of Interferon-Induced Transmembrane Protein 3 (IFITM3) and Gamma-Secretase in Microglia
|
Yueming Li
|
2022-02-15
|
Neuroinflammation Contributions to Alzheimer’s Disease: Role of the Choroid Plexus
|
Maria Lehtinen
Liisa Myllykangas
|
2022-02-15
|
Role of Checkpoint Molecule TIM-3 in Regulating Microglia in Alzheimer’s Disease
|
Vijay K. Kuchroo
|
2022-02-14
|
Contribution of Skull Bone Marrow-Derived Cells to Alzheimer’s Disease
|
Jonathan Kipnis
|
2022-02-14
|
Alzheimer’s Disease Drug Discovery and Development Consortium: High-Throughput Drug Screening for Alzheimer’s Disease Using Three-Dimensional Human Neural Culture Systems
|
Doo Yeon Kim
Luisa Quinti
|
2022-02-14
|
Apolipoprotein E and Immunometabolism in Alzheimer’s Disease
|
Lance Johnson
Josh Morganti Ramon Sun
|
2022-02-14
|
Targeting Microglial TSG101 for Synaptic Protection and Cognitive Enhancement in Alzheimer’s Disease
|
Seiko Ikezu
Tsuneya Ikezu
|
2022-02-14
|
Alzheimer’s Disease Drug Discovery and Development Consortium: Modulating CD33 Function and Neuroinflammation as a Therapeutic Approach for Alzheimer’s Disease
|
Ana Griciuc
|
2022-02-14
|
CIRCUITS: A Unified Approach to Actionable Alzheimer’s Disease Signatures
|
Winston Hide
|
2022-02-14
|
Signaling Function of TREM2 Cleavage Products, Which are Affected by Agonistic Antibodies to the Stalk Region
|
Christian Haass
Kai Schlepckow
|
2022-02-14
|
Revealing New Genes and Pathways at the Intersection of Lipotoxic and Genetic Risk for Alzheimer’s Disease
|
Anna Greka
Beth Stevens
|
2022-02-14
|
Understanding the Mechanism Underlying Vaccination for Alzheimer’s Disease
|
Charles L. Greenblatt
Benjamin Y. Klein Ofer N. Gofrit
|
2022-02-14
|
Systems Integration and Therapeutics Translation in Alzheimer’s Disease
|
Alison Goate
Edoardo Marcora
|
2022-02-14
|
T-Cell Epigenetics in Alzheimer’s Disease
|
David M. Gate
|
2022-02-14
|
Development of Human cGAS Inhibitors to treat Alzheimer’s Disease
|
Li Gan
Subhash Sinha
|
2022-02-11
|
Air Pollution and Alzheimer’s Disease Risk Interact With Premature Aging of Neural Stem Cells and Apolipoprotein E Alleles
|
Caleb Finch
Michael A. Bonaguidi
|
2022-02-11
|
Tau and Amyloid Beta are Innate Immune Antimicrobial Peptides in the Brain
|
William Eimer
|
2022-02-11
|
Influence of Plaque Vicinity on Microglial and Astrocyte Gene Expression; Role of Human Tau and TREM2
|
Frances Edwards
John Hardy
|
2022-02-11
|
Harnessing Meningeal Lymphatics and Immunity to Alleviate APOE4-Induced Brain Dysfunction
|
Sandro Da Mesquita
|
2022-02-11
|
Understanding the Role of Natural Amyloid Beta-Specific B Cell Responses in Alzheimer’s Disease Progression
|
Marco Colonna
|
2022-02-11
|
Targeted Recruitment of Underrepresented Americans for Brain Donation Registration
|
Brain Donor Project
|
2022-02-10
|
Disentangling the Role of Intracranial Arteriosclerosis in Alzheimer’s Disease
|
Daniel Bos
Frank J. Wolters Geert Jan Biessels Julia Neitzel Meike Vernooij
|
2022-02-10
|
Establishing the Molecular and Cellular Mechanisms and Biomarkers of APOE4-Mediated Susceptibility to Tau-Related Cognitive Impairments
|
Joel Blanchard
|
2022-02-10
|
Effects of Depalmitoylation and ACAT Inhibition on Axonal Amyloid Beta Generation Via MAM-Associated palAPP
|
Raja Bhattacharyya
Rudy Tanzi
|
2022-02-10
|
CIRCUITS: Characterizing Epigenetic Biomarkers of Human Cognitive Aging
|
Lars Bertram
|
2022-02-10
|
Brain Entry and Exit Consortium: Glymphatic-Lymphatic Coupling in Alzheimer’s Disease
|
Helene Benveniste
Allen Tannenbaum
|
2022-02-10
|
The Role of Astrocyte-Secreted Insulin-Like Growth Factor Binding Protein 2 (IGFBP2) in the Progression of Alzheimer’s Disease
|
Nicola Allen
|
2022-02-10
|
Identifying Blood-Brain Barrier (BBB) Enhancers and Role of Neutrophils in a 3-D BBB Vascularized Model of Alzheimer’s Disease
|
Roger D. Kamm Se Hoon Choi
|
2022-01-11
|
CIRCUITS: Consortium to Infer Regulatory Circuits and Uncover Innovative Therapeutic Strategies—Production Group
|
Manolis Kellis
Li-Huei Tsai
|
2021-02-23
|
A Transcriptional Rejuvenation Signature for Alzheimer’s Disease
|
Tony Wyss-Coray
|
2021-01-29
|
Personalized Disease Prediction for Alzheimer’s Disease Using Proteome Profiling: The EPIC4AD Study
|
Christina M. Lill
Lars Bertram
|
2021-01-29
|
Gut Microbiota, Endothelial Dysfunction and Tau-Mediated Cognitive Impairment
|
Giuseppe Faraco
Costantino Iadecola
|
2021-01-29
|
Role of Secreted Protein Acidic and Rich in Cysteine (SPARC) in Immunometabolic Control of Age-Related Inflammation
|
Vishwa Deep Dixit
|
2021-01-29
|
Mechanisms of Tau Propagation Across the Plasma Membrane
|
Marc Diamond
|
2021-01-29
|
Understanding and Mimicking the Biological Effects of the Phospholipase C-gamma-2 P522R Variant That Protects Against Alzheimer’s Disease
|
Rik van der Kant
Philip Scheltens
|
2021-01-29
|
Identification of CD33 Antagonists
|
Subhash Sinha
|
2021-01-05
|
Small Molecule Activators of PLC-gamma-2 as Novel Therapeutics for Alzheimer’s Disease
|
Qisheng Zhang
John Sondek Kenneth Pearce
|
2020-12-21
|
Investigating the Contribution of Astrocytic-Dependent Inflammation on Amyloid-Induced Tau Pathology
|
Gilbert Gallardo
|
2020-12-21
|
Uncovering the Molecular Mechanism of Selected Drug Candidates Derived from Systematic Alzheimer’s Drug Repositioning
|
Stephen T.C. Wong
|
2020-12-21
|
Proteomics of Alzheimer’s Disease Three-Dimensional Cultures
|
Weiming Xia
|
2020-12-21
|
Adult Human iNeurons: A Next-Generation Drug Screening Platform for Alzheimer’s Disease
|
George S. Bloom
Elizabeth R. Sharlow John S. Lazo
|
2020-12-21
|
Neuroimmune Consortium: Examining the Role of Human Microglia in the Transition Between Parenchymal and Vascular Amyloid Beta Pathology
|
Mathew Blurton-Jones
|
2020-12-18
|
Novel Entry Routes for Therapeutic Biologicals to the Brain
|
Maarten Dewilde
Bart De Strooper
|
2020-12-18
|
Characterizing Gut Microbiome Synergy With Emphasis on Mycobiome and Its Impact on Alzheimer’s Disease (AD) Pathology in AD Mouse Models
|
Deepak Kumar Vijaya Kumar
Nanda Kumar Navalpur Shanmugam Rudy Tanzi William Eimer
|
2020-12-18
|
High-Throughput Drug Screening for Alzheimer’s Disease Using Three-Dimensional Human Neural Culture Systems
|
Doo Yeon Kim
Luisa Quinti
|
2020-12-18
|
Modulating CD33 Function and Neuroinflammation as a Therapeutic Approach for Alzheimer’s Disease
|
Ana Griciuc
|
2020-12-18
|
Neuroimmune Consortium: Understanding the Consequences of Noncoding Alzheimer’s Disease Risk Alleles on Microglia Function
|
Beth Stevens
|
2020-12-15
|
Neuroimmune Consortium: Leveraging Enhancer Landscapes to Decode Alzheimer’s Disease Risk Alleles in Microglia
|
Christopher K. Glass
|
2020-12-15
|
Effect of Gut Microbiome Dysbiosis on Neuroinflammation and Amyloid Beta Deposition: A Longitudinal Micro-PET Study in Alzheimer’s Transgenic Mice
|
Sangram S. Sisodia
|
2020-12-15
|
Discovery and Development of Chemical Probes to Elucidate MS4A Protein Function
|
Jacob Hooker
|
2020-12-15
|
Neuroimmune Consortium: Investigation of Alzheimer’s Disease Risk Alleles in Astrocytes—Focus on Cholesterol Transport and Microglia Interactions
|
Shane Liddelow
|
2020-12-15
|
Sex Differences in Alzheimer’s Disease Progression: Framingham Heart Study
|
P. Murali Doraiswamy
|
2020-12-10
|
Single Nucleus RNA Sequencing Analysis of ACE1 R1284Q Knockin Mice
|
GENEWIZ
Leah Cuddy Robert Vassar
|
2020-11-12
|
Sex Matters: Understanding the Influence of Sex and Apolipoprotein E (APOE) Genotype on Hippocampal Plasticity and Cognition
|
Liisa Galea
|
2020-11-11
|
VGF-Derived Peptide Therapy for Alzheimer’s Disease: Studies of Mouse and Human TLQP-21 and its Receptor, C3aR1
|
Michelle E. Ehrlich
Stephen R. Salton
|
2020-11-06
|
The NEDD4-1 and PKCa Connection in Alzheimer’s Disease
|
Gentry Patrick
|
2020-11-05
|
Creation of a Fibroblast/iPS Cell Bank to Facilitate Peripheral/Brain Comparisons, and Allow Molecular Investigations into Molecular Mechanisms Underlying Differences in Disease Aggressiveness
|
Bradley T. Hyman
|
2020-11-05
|
Investigating the Role of Tau Protein in Neuronal Senescence Induction and Maintenance
|
Miranda Orr
|
2020-11-04
|
SFRP1 as a Therapeutic Target and Diagnostic/Prognostic Factor in Alzheimer’s Disease
|
Paola Bovolenta
Pilar Esteve
|
2020-11-04
|
Comprehensive Analyses of Chronic Efficacy Studies with GSM 776890 for Submission of the Pre-IND Brochure to the FDA Prior to Pre-IND Meeting and IND Filing for the SAD/MAD Phase I Safety/Toxicity and Ultimately for Phase II and Phase III Efficacy Clinical Trials to Support the NDA
|
Steven L. Wagner
|
2020-08-04
|
Microbes and Alzheimer’s Disease: Metagenomics on Saliva, Cerebrospinal Fluid, Blood and Brain
|
Nanda Kumar Navalpur Shanmugam
Deepak Kumar Vijaya Kumar Rudy Tanzi William Eimer
|
2020-08-03
|
Regulation by Apolipoprotein E of Selective Neuronal Vulnerability to Alzheimer’s Disease
|
Jean-Pierre Roussarie
|
2020-04-13
|
Counteracting Pathogenic Events in Alzheimer’s Disease with Peripheral or Central Apolipoprotein E
|
Takahisa Kanekiyo
|
2020-04-13
|
Fleming APOE Consortium: Assessing the Added Diagnostic Value of Peripheral Apolipoprotein E Protein Levels in Current Blood-Based Biomarker Assays for Central Nervous System Amyloidosis
|
Randall J. Bateman
|
2020-04-13
|
In Vivo Characterization of a Loss-of-Function GGA3 Rare Variant Associated with Alzheimer’s Disease
|
Giuseppina Tesco
|
2020-03-24
|
Characterization of Alzheimer’s Disease Molecular Biomarker Profiles Throughout the Pathobiological Continuum
|
Krista L. Moulder
|
2020-02-18
|
ABCA7 Loss of Function in Aging and Alzheimer’s Disease
|
Takahisa Kanekiyo
Guojun Bu
|
2020-02-18
|
Application of Machine Learning Methods in Alzheimer’s Disease Clinical Trials
|
Ali Ezzati
Richard Lipton
|
2020-02-18
|
Molecular Signatures of APOE-Mediated Blood-Brain Barrier Dysfunction Causing Neuronal and Synaptic Dysfunction
|
Berislav Zlokovic
|
2020-01-09
|
An Innovative Study of the Pupil Light Reflex in Alzheimer’s Disease
|
Shirley Wray
|
2020-01-09
|
Targeting the Microbiome and Microglia in Alzheimer’s Disease
|
Howard L. Weiner
Laura Cox
|
2020-01-09
|
Harnessing Big Data to Understand Alzheimer’s Disease Risk
|
Brad A. Racette
Alejandra Camacho-Soto Susan Searles Nielsen
|
2020-01-09
|
Tau and Amyloid Beta are Innate Immune Antimicrobial Peptides in the Brain
|
William Eimer
Deepak Kumar Vijaya Kumar Rudy Tanzi
|
2020-01-09
|
Alzheimer’s Genome Project™
|
Rudy Tanzi
|
2020-01-09
|
The Role of Clusterin in Tau Pathology
|
John D. Fryer
|
2019-12-26
|
Evaluation of the Effect of Cell Type-Specific Deletion of ESCRT Genes on the Spread of Tau Pathology
|
Tsuneya Ikezu
|
2019-12-24
|
Berg Brain Entry and Exit Consortium: Direct Migration of Myeloid Cells from the Skull Marrow to the Brain Through Anatomical Channels: Adding Fuel to the Fire in Alzheimer’s Disease
|
Fanny Herisson
|
2019-12-17
|
Berg Brain Entry and Exit Consortium: Patch-Seq Analysis of the Choroid Plexus Epithelial Cell Barrier in Homeostasis and in Alzheimer’s Disease
|
Fernanda Marques
|
2019-12-17
|
Berg Brain Entry and Exit Consortium: Crosstalk of Central Nervous System Barriers and Clearance Routes in Homeostasis and Alzheimer’s Disease
|
Jonathan Kipnis
|
2019-12-17
|
Berg Brain Entry and Exit Consortium: Assessment of Antibody-Based Drug Trafficking Across the Blood-Brain Barrier Via Skull-Meninges Connections
|
Ali Ertürk
|
2019-12-17
|
Berg Brain Entry and Exit Consortium: Identifying the Blood-Brain Barrier Changes During Alzheimer’s Disease
|
Richard Daneman
|
2019-12-17
|
Berg Brain Entry and Exit Consortium: Human 3D Neurovascular Interaction and Meningeal Lymphatics Models with Application to Alzheimer’s Disease
|
Se Hoon Choi
Roger D. Kamm
|
2019-12-17
|
Alzheimer’s Risk is Higher in Women: Identification of Female-Specific Brain Bioenergetic Targets
|
|
2019-11-05
|
Patient-Based Structural and Functional Biology of Tauopathies
|
Anthony Fitzpatrick Leonard Petrucelli
|
2019-11-04
|
Interpretation of Noncoding Risk Alleles for Alzheimer’s Disease
|
Christopher K. Glass
|
2019-08-27
|
Assessing the Links Between the Ms4a Risk Genes, Microglia and Alzheimer’s Disease
|
Sandeep Robert Datta
|
2019-08-27
|
Mechanisms for Alzheimer’s Disease-associated SORLA Mutations in Microglia and Neurons in AD Pathogenesis
|
Huaxi Xu Timothy Huang
|
2019-06-11
|
Understanding Molecular Biomarker Changes in Alzheimer’s Disease Using Genetically Defined Mouse Models
|
Mathias Jucker
Stephan Kaeser
|
2019-06-11
|
The Role of MGnD-neurodegenerative Clec7a+ Microglia in an Alzheimer’s Disease Mouse Model
|
Oleg Butovsky
|
2019-06-11
|
PEGASUS Clinical Study of AMX0035 in Alzheimer’s Disease
|
Amylyx
|
2019-03-15
|
The Role of the Contact System in Alzheimer’s Disease
|
Erin H. Norris Sidney Strickland
|
2019-01-10
|
The Development of DNA-Encoded Libraries to Discover Therapeutically Valuable Low Molecular Weight Compounds for Alzheimer’s Disease
|
Marc Flajolet Subhash Sinha
|
2019-01-10
|
Amyloid Beta-Mediated Inhibition of Gamma-Secretase Activity Induces Alzheimer’s Disease-Relevant Cellular Phenotypes
|
William C. Mobley
Lucía Chávez-Gutiérrez
|
2019-01-10
|
The Neuroprotective Glial Barrier: A Multicellular Reaction with Therapeutic Potential in Alzheimer’s Disease
|
Jaime Grutzendler
|
2019-01-10
|
Neurobiological Basis of Cognitive Impairment in African Americans: Deep Phenotyping of Older African Americans at Risk of Dementia—The Dementia (in) African American Population Phenotyping (for) Potential Elevated Risk (DAAPPER) Study
|
Henry Paulson
Benjamin M. Hampstead, Ph.D., ABPP/CN Bruno Giordani, Ph.D.
|
2019-01-10
|
Interleukin-3 in Alzheimer’s Disease
|
Filip Swirski
|
2018-12-27
|
Senescent Cells and Alzheimer’s Disease
|
Darren J. Baker
|
2018-12-27
|
Pharmacologically Protecting and Rescuing Synapses from Beta Amyloid by Raising Synaptic PSD-95
|
Roberto Malinow
|
2018-12-27
|
Neuroprotective Effects of the Exercise Hormone Irisin in Alzheimer’s Disease
|
Se Hoon Choi
Christiane Wrann
|
2018-12-27
|
The Effect of Chronic Gamma-Secretase Modulation on the Prevention of Traumatic Brain Injury-Provoked and Alzheimer’s Disease-Relevant Biochemical, Pathological and Behavioral Alterations
|
Steven L. Wagner
Brian P. Head
|
2018-12-24
|
Human-Specific Evolution of CD33: Evolutionary Relationship to Ancient Host-Pathogen Interactions and Current Implications for Alzheimer’s Disease
|
Ajit Varki
Nissi Varki Pascal Gagneux
|
2018-12-24
|
The Role of Impaired Synaptic Vesicle Machinery Proteostasis in Alzheimer’s Disease Pathogenesis
|
Jeffrey Savas
|
2018-12-24
|
Role of Microglial Matricellular Protein SPARC in Control of Inflammasome Activation
|
Vishwa Deep Dixit
|
2018-12-24
|
Study of Reactive Astrocytes-Derived Oxidative Stress and Proinflammation Leading to Neurodegenerative Microglial Activation in Alzheimer’s Disease
|
Hansang Cho
|
2018-12-24
|
Alzheimer’s Disease Pharmacomics in 3-D
|
Weiming Xia
|
2018-12-20
|
Single-Cell Analysis of 3D Human Triculture Model of Alzheimer’s Disease: The Impact of AD-Associated Genetic Variants
|
Joseph Park
Rudy Tanzi
|
2018-12-20
|
Inhibiting CD33 Function and Modulating Microglial Activation State for Alzheimer’s Disease Therapy
|
Ana Griciuc
|
2018-12-20
|
Identifying the Blood-Brain Barrier Changes During Alzheimer’s Disease
|
Richard Daneman
|
2018-12-18
|
Reversal of Tau Pathology by an Adenosine A1 Receptor Antagonist
|
Eva-Maria Mandelkow
Anja Schneider Eckhard Mandelkow
|
2018-12-18
|
Dietary Salt, Tau Phosphorylation and Cognitive Impairment
|
Giuseppe Faraco
Costantino Iadecola
|
2018-12-18
|
Physiological Method for Early Detection of Synaptic Vulnerability in Alzheimer’s Disease Model Animals
|
Riqiang Yan
Srdjan D. Antic
|
2018-12-17
|
Effects of Cerebrovascular Insufficiency and Exercise on the Alzheimer’s Brain
|
Eng H. Lo
|
2018-12-17
|
The Circadian Clock Modulates Neurodegeneration in Alzheimer’s Disease Via REV-ERBA (Year 1)
|
Erik S. Musiek
|
2018-12-13
|
Central Clock Influence on Alzheimer’s Disease Pathogenesis
|
Geraldine J. Kress
|
2018-12-13
|
Understanding Human Brain Resilience to Alzheimer’s Pathology
|
Teresa Gomez-Isla
|
2018-10-15
|
Validation of Endogenous Human Antibodies That are Correlated With Avoiding Alzheimer’s Disease and Their Corresponding Antigens, for Immunotherapeutic Development
|
Charles Glabe
|
2018-08-27
|
Targeting Cell Cycle Re-entry Using 3-D Neuron Cultures
|
Elizabeth R. Sharlow George S. Bloom John S. Lazo
|
2018-08-27
|
Mechanisms By Which the Gut Microbiome Influences Amyloid Deposition and Neuroinflammation in the APPswe/ PS1DE9 Mouse Model of Amyloid Beta Amyloidosis
|
Sangram S. Sisodia
|
2018-08-27
|
Gut Microbiome-Mediated Shifts in Amyloid Beta Deposition in a Humanized Alzheimer’s Disease Mouse Model
|
Deepak Kumar Vijaya Kumar
|
2018-08-27
|
VGF, a Novel Therapeutic Effector of Alzheimer’s Disease Pathogenesis and Progression
|
Stephen R. Salton
Michelle E. Ehrlich
|
2018-08-27
|
Amyloid Beta Kinetics and Enhancing the Diagnostic and Prognostic Cerebrospinal Fluid Biomarkers of Alzheimer’s Disease
|
Randall J. Bateman
Norelle Wildburger, Ph.D.
|
2018-08-27
|
Exploring Sex Differences in AD Pathogenesis Using 3-D Human Non-Cell-Autonomous Models
|
Doo Yeon Kim
Daniel Irimia
|
2018-08-27
|
A Microfluidics-Based Human Brain Cell 3-D Culture System in Alzheimer’s Disease
|
Hansang Cho
|
2018-08-27
|
Interactions Among TREM2, APOE and Sex
|
Caleb Finch Christian Pike
|
2018-08-27
|
TREM2: Role in Modulating Amyloid Beta and Tau-Related Pathologies and Neurodegeneration
|
David Holtzman Marco Colonna
|
2018-08-27
|
Investigating the Mechanism of APOE4-associated Neuronal Hyperactivity in the Entorhinal Cortex and its Effect on Tauopathy Propagation
|
Karen Duff Tal Nuriel
|
2018-08-27
|
Uncovering the Molecular Mechanism of Selected Drug Candidates Derived from Systemic Alzheimer’s Drug Repositioning
|
Stephen T.C. Wong
|
2018-08-27
|
Alzheimer’s Disease Stem Cell Drug Screening in 3-D
|
Weiming Xia
|
2018-08-09
|
Compounds Modulating Microglial Uptake of Amyloid Beta and CD33-Targeted Immunotherapy for Alzheimer’s Disease
|
Ana Griciuc
Rudy Tanzi
|
2018-08-09
|
Evaluation of Blood-Brain Barrier (BBB) Penetration of Alzheimer’s Drug Targets, and Identification of BBB Integrity Enhancers
|
Roger D. Kamm Se Hoon Choi
|
2018-08-09
|
Gene Expression Throughout Development of Pathology in APPKI Mice; Effects of Human Tau and Aging
|
Frances Edwards John Hardy
|
2018-08-09
|
Novel Chemical Modulators for BACE1-Mediated Cleavage of Amyloid Beta Precursor Protein
|
Tae-Wan Kim
|
2018-08-09
|
Cerebrovascular Dysfunction in AD: Targeting the Mechanisms of Vascular Activation
|
Paula Grammas
|
2018-08-09
|
Biochemical Mapping of the GSM Binding Site of Novel Pyridazine-Derived Small Molecule Gamma-Secretase Modulators
|
Steven L. Wagner
Yueming Li
|
2018-08-09
|
Stimulating Proteasome Activity for the Treatment of Alzheimer’s Disease (Year 1)
|
Hermann Steller
|
2018-08-09
|
Evaluation of Sleep-EEG in Transgenic Mice
|
PsychoGenics
|
2018-08-09
|
Treating with Gamma-Secretase Modulators (GSMs) to Prevent Neurodegeneration in Mouse Models of Down Syndrome
|
William C. Mobley
|
2018-08-09
|
Microglial TAM Receptors as Modulators of Alzheimer’s Pathology
|
Greg Lemke
|
2018-08-09
|
Synapse Pruning by Astrocytes: A Potential New Target for Treating Alzheimer’s Disease
|
Won-Suk Chung
|
2018-08-09
|
Targeting Reactive Astrocytes for Therapeutic Intervention in Alzheimer’s Disease
|
Gilbert Gallardo
|
2018-08-09
|
Scientific Directions for the Exploration of Racial Disparities in Alzheimer’s Disease
|
Krista L. Moulder
|
2018-07-24
|
Neurotoxic Reactive Astrocytes in Alzheimer’s Disease
|
Shane Liddelow
|
2018-07-24
|
Imaging Microglial Homeostasis and Disruption: P2RY12 Radiotracer Development
|
Jacob Hooker Michael Placzek
|
2018-07-24
|
Targeting Beneficial Innate Immunity in Alzheimer’s by Interleukin-1 Receptor-Associated Kinase M Deletion
|
Jeannie Chen Karen Chang
|
2018-07-24
|
Role of Ataxin-1 in Regulating BACE1 Activity (Year 2)
|
Jaehong Suh, Ph.D.
|
2018-07-24
|
Temporal Analysis of Infection in Alzheimer’s Disease Models
|
Judith Steen
|
2018-07-24
|
Chronic Viral Neuroinfection Mediates Amyloid Beta Deposition in Transgenic Alzheimer’s Disease Mice
|
Robert Moir
|
2018-06-22
|
Neuroimmune Molecular Imaging: Redefining the Landscape of Opportunities in Alzheimer’s Disease
|
Jacob Hooker
|
2018-06-19
|
The Role of Neurexins in Alzheimer’s Disease (Year 2)
|
Meng Chen Rudy Tanzi
|
2018-06-19
|
PICALM Gene Therapy and Drug Screening for Amyloid Beta Clearance (Year 3)
|
Berislav Zlokovic
|
2018-06-19
|
Microglial Heterogeneity and Transcriptional State Changes in Alzheimer’s Disease
|
Beth Stevens
|
2018-06-19
|
Stable Isotope Labeling and Quantitative Mass Spectrometry Imaging of Alzheimer’s Disease Pathology in Human Brain
|
Katherine Schwetye
|
2018-04-27
|
Inhibition of Tau Pathology in Human Neurons
|
Benjamin Wolozin
|
2017-08-01
|
Understanding the Effect of APOE on Tau-Mediated Neurodegeneration
|
David Holtzman
|
2017-07-25
|
Effects of Peripheral APOE on Central Nervous System Functions and AD Pathogenesis
|
Guojun Bu
|
2017-07-25
|
The Role of APOE in Microglia Regulation in Neurodegeneration
|
Oleg Butovsky
|
2017-07-25
|
APOE Consortium: Toward Developing High-Density Lipoprotein Enriched in Apolipoprotein E as a Potential Biomarker and Therapeutic Targeting Vascular Contributions to Alzheimer’s Disease
|
Cheryl Wellington
|
2017-07-25
|
APOE Proteoforms in Human CNS and Validation of APOE Pharmacodynamic Translational Markers
|
Randall J. Bateman
|
2017-07-25
|
Impact of APOE and Sex on Vulnerable Neuron-Specific Functional Network
|
Paul Greengard
|
2017-07-25
|
Propagation of Tauopathy and Ubiquitin Proteasome System Dysfunction: Impact and Rescue with a UPS Activator
|
Karen Duff Natura Myeku
|
2017-03-01
|
Role of ATXN1 in Regulating BACE1 Activity
|
Jaehong Suh, Ph.D.
|
2017-01-26
|
CIRCUITS: Integrating Functional Maps to Discover MicroRNAs in Alzheimer’s Disease
|
Winston Hide
|
2017-01-05
|
CIRCUITS: Impact of Genetic, Epigenetic and Cellular Variants on Alzheimer’s Disease Pathology
|
Rudolf Jaenisch
Joseph R. Ecker
|
2017-01-05
|
CIRCUITS: Identifying Novel Epigenetic Biomarkers of Human Cognitive Aging
|
Lars Bertram
|
2017-01-05
|
CIRCUITS: Production Center for Reference and Variation Gene-Regulatory Maps
|
Manolis Kellis
Li-Huei Tsai
|
2017-01-05
|
CIRCUITS: Functional Analysis of Alzheimer’s Disease Risk Genes Using Human-Induced Pluripotent Stem Cells
|
Li-Huei Tsai Manolis Kellis
|
2017-01-05
|
CIRCUITS: IPS Cells and the Human Brain
|
Bradley T. Hyman
|
2017-01-05
|
Interpreting Alzheimer’s Disease-Associated Genetic Variation at Enhancer Regions
|
Andreas R. Pfenning
|
2017-01-04
|
The APOE Mimetic Therapeutic Peptide CN-105 Attenuates AD Pathology and Improves Functional Outcomes in a Murine Model of Alzheimer’s Disease
|
Daniel Laskowitz
|
2017-01-04
|
Intersection of Microglial Transcriptomes to Identify Key Alzheimer’s Pathways of Brain Phagocytes
|
Sam Gandy
|
2017-01-04
|
Regulation of Microglial Lysosome Acidification
|
Frederick Maxfield
|
2016-12-06
|
Identification of a Protective Human Immune Response for Alzheimer’s Disease
|
Charles Glabe
|
2016-12-06
|
Characterization of Certain Human APOE Targeted Gene Replacement Mice
|
David Holtzman Jason D. Ulrich
|
2016-10-28
|
Binding Site Characterization of a Novel Pyridazine-Derived Class of γ-Secretase Modulators
|
Steven L. Wagner
|
2016-09-23
|
Search for Female-Specific Genetic Factors Contributing to Risk for Alzheimer’s Disease
|
Rudy Tanzi
|
2016-09-07
|
Impact of Inflammasome Deactivation on Alzheimer’s Disease
|
Vishwa Deep Dixit
|
2016-09-07
|
Nanobodies to Cross the Blood-Brain Barrier
|
Bart De Strooper
Maarten Dewilde
|
2016-09-01
|
SORLA Attenuates Abeta Toxicity Through Interactions With EphA4
|
Huaxi Xu
|
2016-08-17
|
Early Role of Microglia in Synapse Loss in Alzheimer’s Disease
|
Beth Stevens
|
2016-07-15
|
The Role of Meningeal Lymphatics in Cleansing the Brain: Implications for Alzheimer’s Disease
|
Jonathan Kipnis
|
2016-07-05
|
Will Restoration of Normal Glymphatic Function Slow Progression of Cognitive Decline and Amyloid Plaques in a Murine Alzheimer Model?
|
Maiken Nedergaard
|
2016-07-05
|
Therapeutic Modulation of TREM2 Activity
|
Christian Haass
|
2016-07-05
|
Mechanisms By Which the Gut Microbiome Influences Amyloid Deposition and Neuroinflammation in Mouse Models of Alzheimer’s Disease
|
Sangram S. Sisodia
|
2016-07-05
|
Investigating the Mechanism of Entorhinal Cortex Hypermetabolism in APOE4 Targeted Replacement Mice
|
Karen Duff Tal Nuriel
|
2016-05-12
|
Role of Neurexins in Alzheimer’s Disease Pathophysiology
|
Rudy Tanzi
|
2016-05-04
|
Activation of the 26S Proteasome for the Treatment of Alzheimer’s Disease
|
Alfred L. Goldberg
|
2016-04-28
|
Modeling DNA Methylation Changes in Alzheimer’s Disease Using Human-Induced Pluripotent Stem Cells
|
Rudolf Jaenisch
|
2016-04-28
|
Modeling Alzheimer’s Disease in Specific Subtypes of Human Neurons Through Direct Neuronal Reprogramming of Patient Fibroblasts
|
Andrew S. Yoo
|
2016-04-26
|
Alzheimer Disease-Associated Mutations in Protein Kinase C
|
Alexandra C. Newton
|
2016-04-26
|
Pathway Cross-talks Associated with Sex and Risk for Alzheimer’s Disease
|
P. Murali Doraiswamy
|
2016-04-26
|
Acceleration of FDA-Required GLP Gene Toxicity Studies with the GSM BPN-15606
|
Steven L. Wagner
|
2016-04-26
|
In Vitro and In Vivo Analysis of APP Variants
|
Sangram S. Sisodia
|
2016-04-26
|
A Combination of Anti-Abeta and Growth Factor Therapy for AD
|
Mark H. Tuszynski
|
2016-04-26
|
ABCA7 in Brain Homeostasis and Alzheimer’s Disease
|
Guojun Bu
Takahisa Kanekiyo
|
2016-02-29
|
The Role of PICALM Mutations in Alzheimer’s Disease
|
Berislav Zlokovic
Zhen Zhao
|
2016-01-12
|
Molecular and Cellular Mechanisms of ACE1 Variant in Alzheimer’s Disease
|
Robert Vassar
|
2016-01-12
|
Studying the Functional Consequences of Alzheimer’s Disease Risk Variants in the CLU and ABCA7 Genes Using Both Human and Mouse Models
|
Li-Huei Tsai
|
2016-01-12
|
Functional Characterization of GGA3 Mutations Associated with Alzheimer’s Disease
|
Giuseppina Tesco
|
2016-01-11
|
Amyloid Beta Expression Protects the Brain from Herpes Simplex Virus
|
Robert Moir
|
2016-01-11
|
Tau Missorting in AD—Causes and Consequences
|
Eckhard Mandelkow
Eva-Maria Mandelkow
|
2016-01-11
|
Extracellular Vesicle-Based Targeting of CD33-Mediated Pathology for Alzheimer’s Disease Therapy
|
Casey A. Maguire
|
2016-01-11
|
Discovery of Chemical Compounds That Induce Degradation of APP Beta-CTF
|
Victor Bustos
|
2016-01-11
|
Stem Cell Approach to Investigating the Phenomenon of Brain Insulin Resistance
|
Sam Gandy
|
2016-01-11
|
Genetic Targets to Block Tau Propagation: Test Knockdown of Heparan Sulfate Proteoglycan Genes In Vivo
|
Marc Diamond
|
2016-01-11
|
Evaluation of AMX0035, a Neuroprotecting and M1-Deactivating Therapeutic, in an Immunological Model of AD
|
Amylyx
|
2016-01-11
|
The Biological Impact of TREM Locus Mutations in Alzheimer’s Disease
|
Marco Colonna
David Holtzman
|
2015-11-05
|
Targeting Beneficial Innate Immunity in Alzheimer’s by IRAK-M Deletion
|
Terrence Town
|
2015-11-04
|
Role of the Gut Microbiome in AD Pathology and the Potential of Probiotic Therapeutic Strategies
|
Deepak Kumar Vijaya Kumar Robert Moir
|
2015-11-03
|
TREM2 Function and Dysfunction in Alzheimer’s Disease
|
Christian Haass
|
2015-10-29
|
Rejuvenation of Microglia in Brain Aging and Neurodegeneration
|
Tony Wyss-Coray
|
2015-10-29
|
Systemic Inflammatory Networks in Alzheimer’s Disease
|
Filip Swirski
Matthias Nahrendorf
|
2015-10-29
|
3DDS: Alzheimer’s Disease Drug Discovery in 3-D
|
Weiming Xia
|
2015-10-22
|
Regulation of RNA Translation by MAPT in Alzheimer’s Disease
|
Benjamin Wolozin
|
2015-10-01
|
Use of High-Content Drug Screening and Systems Biology Modeling on a Novel 3-D Cell Model to Repurpose Known Drugs for Alzheimer’s Disease
|
Stephen T.C. Wong
|
2015-09-30
|
A 3-D Human Neural Cell Culture System for Studying Neuron-Microglia Interaction in Alzheimer’s Disease
|
Hansang Cho
|
2015-09-30
|
Development of Novel APP Dimerization Inhibitors That Lower Abeta Levels
|
Carmela R. Abraham
|
2015-09-29
|
Role of Blood-Brain Barrier Function in Alzheimer’s Disease Pathogenesis Investigated Using a 3-D Microfluidic Platform
|
Se Hoon Choi
Roger D. Kamm
|
2015-09-29
|
Microglial Core/CD33 and Alzheimer’s Disease: From Biology to Therapy
|
Ana Griciuc Rudy Tanzi
|
2015-09-29
|
3-D Neural Core/High-Throughput Drug Screening for Alzheimer’s Disease Using 3-D Human Neural Culture Systems
|
Doo Yeon Kim
|
2015-09-29
|
Cell Cycle Re-entry in 3-D Human Neuron Cultures
|
John S. Lazo
George S. Bloom
|
2015-09-28
|
The Putative Role of Red Blood Cell CR1 Levels in Amyloid-Beta Clearance and Alzheimer’s Disease Pathogenesis
|
Cynthia A. Lemere
|
2015-09-28
|
PICALM Gene Therapy and Drug Screening for Abeta Clearance
|
Berislav Zlokovic Beverly L. Davidson
|
2015-09-28
|
Understanding Reactive Astrocytes and Their Roles in Alzheimer’s Disease
|
Ben Barres
|
2015-09-28
|
Uncovering Determinants of Neuronal Vulnerability in Alzheimer’s Disease
|
Paul Greengard
|
2015-09-24
|
BIN1 in Alzheimer’s Disease Neuropathology
|
Gopal Thinakaran
|
2015-09-24
|
Lead Optimization and Lead Evolution of Potent SGSMs for the Treatment of Alzheimer’s Disease
|
Steven L. Wagner
Rudy Tanzi
|
2015-07-02
|
Analytical and Statistical Tools for Sequence Analysis for Alzheimer’s Disease
|
Christoph Lange
|
2015-06-29
|
Optimization of Pharmacalogic Properties of Molecular Tweezers
|
Gal Bitan
|
2015-06-25
|
The Role of Microbial Immune Responses in Alzheimer’s Disease
|
Sangram S. Sisodia
|
2015-06-25
|
Long Abetas, Intraneuronal Amyloid and an Alternative Amyloid Hypothesis of Alzheimer’s Disease
|
Charles Glabe
|
2015-06-25
|
The Role of the KIBRA Gene in Abeta Regulation of AMPAR Trafficking
|
Richard L. Huganir
|
2015-06-25
|
Generation of Neural Progenitor Cells Overexpressing Alzheimer’s Disease Genes with Familial Mutations and Analysis of Pathological Changes of Alzheimer’s Cells in Vivo
|
Doo Yeon Kim
|
2015-04-21
|
Identification of Functional Properties of Human Alzheimer’s Disease Cells That Affect Their Bilateral Interactions with Brain Environment
|
Tamir Ben-Hur
|
2015-04-21
|
G2T Research Models and Materials
|
Taconic Biosciences
|
2015-04-21
|
Genes to Therapies (G2T) Centralized Research Core Oversight
|
Wilma Wasco
|
2015-04-21
|
Development of an APP-specific B-secretase inhibitor for Alzheimer’s disease therapy
|
Lawrence Rajendran
|
2015-01-14
|
The Role of TREML2 in Alzheimer’s Disease
|
Marco Colonna
|
2014-12-16
|
Elucidation of the Molecular Target of Potent γ-Secretase Modulators
|
Steven L. Wagner
|
2014-12-03
|
Generation of iPS Cells and Neurons from Skin Fibroblasts from Subjects with Familial and Sporadic AD
|
Sam Gandy Scott Noggle
|
2014-12-03
|
Air Pollution and APP processing
|
Caleb Finch
|
2014-11-19
|
FXII System’s Effect on Alzheimer’s Disease
|
Sidney Strickland
|
2014-11-19
|
Myeloperoxidase, Imaging and Treatment Target for Alzheimer’s Disease
|
John Chen
|
2014-08-11
|
Orbitrap Fusion Tribrid Mass Spectrometer
|
Randall J. Bateman
|
2014-08-07
|
High-Throughput Multiplex Real-Time PCR For CSF-Biomarker And MicroRNA Profiling In AD
|
Lars Bertram
|
2014-08-04
|
Regulation of Tau Oligomerization by Interaction with TIA-‐1, a Component of Stress Granules
|
Benjamin Wolozin
|
2014-07-17
|
GABAergic inhibitory efficiency and adult neurogenesis in the hippocampus of aged Ts65Dn mice, a model of ‘Alzheimer’s disease in Down syndrome’, after chronic treatment with the monoacylglycerol lipase inhibitor JZL184
|
William C. Mobley
|
2014-07-17
|
Characterizing the role of LOAD-associated variants of DLGAP1 in AD
|
Roberto Malinow
|
2014-07-17
|
The role of PICALM in vascular clearance of amyloid-B and neuronal injury
|
Berislav Zlokovic
|
2014-07-17
|
Molecular mechanisms of synaptic plasticity in the hippocampus: A path to novel therapies
|
Robert C. Malenka
|
2014-07-17
|
Patient-derived Reprogrammed Neurons as a Model to Study Neurodegenerative Diseases in a Dish
|
Marc Tessier-Lavigne
|
2014-07-17
|
Discovery of Alzheimer’s Disease Blood Biomarkers Using Phage Display Technology
|
Yueming Li
|
2014-01-27
|
The Root of Alzheimer’s Disease: Purification and Characterization of Amyloid-beta Oligomers from the Human Brain
|
David L. Brody
|
2013-12-10
|
Vascular Regenerative Therapy for Alzheimer’s Disease
|
Guojun Bu
|
2013-12-10
|
Characterization of the pathological significance of a novel type of vascular amyloid
|
Charles Glabe
|
2013-12-09
|
Sleep and tauopathies: Effect of an anti-tau antibody
|
David Holtzman
|
2013-12-09
|
Elucidation of the mechanism of action of Gamma Secretase Modulators
|
Steven L. Wagner
|
2013-07-10
|
Effects of Inhibitors of Monoacylglycerol Lipase on Behavior and Synaptic Plasticity of Ts65Dn Mice, a Genetic Model of Down Syndrome
|
William C. Mobley
|
2013-06-13
|
Stem Cell Consortium
|
Doo Yeon Kim Kevin Eggan Marc Tessier-Lavigne Sam Gandy Scott Noggle Tamir Ben-Hur
|
2013-03-19
|
Potential for Host Cytotoxicity from Microbially-derived Abeta Oligomers
|
Charles Glabe Rudy Tanzi
|
2013-02-06
|
Antibody Signature of Alzheimer’s Disease: Promise of an Early Diagnostic Test
|
Lucas Restrepo
|
2013-01-31
|
Normalizing Abeta synaptic depression with drugs targeting PICK1
|
Roberto Malinow
|
2013-01-18
|
Investigations of the Mechanism of Action of TagretinR/Bexarotene on Amyloid Clearance in Transgenic Mouse Models
|
Robert Vassar Sangram S. Sisodia
|
2012-12-12
|
Whole Genome Sequencing
|
Rudy Tanzi
|
2012-12-12
|
The roles of Eps homology domain (EHD) proteins and synaptic activity in axon transport of the Alzheimer’s Beta-secretase BACE1 in the brain
|
Robert Vassar
|
2012-12-06
|
BACE1 transcytosis in Alzheimer’s disease pathogenesis
|
Gopal Thinakaran
|
2012-12-06
|
iPS-Derived and Trans-Differentiated Human Neurons as Models to Study Alzheimer’s Disease
|
Marc Tessier-Lavigne
|
2012-12-06
|
The Putative Role of Red Blood Cell CR1 levels in Amyloid Beta Clearance and Alzheimer’s Disease Pathogenesis
|
Cynthia A. Lemere
|
2012-12-06
|
The Role of PICALM in Vascular Clearance of Amyloid Beta
|
Berislav Zlokovic
|
2012-12-05
|
Aβ Oligomers and the Pathogenic Spread of Tau Aggregation: Implications for Alzheimer’s Disease Mechanism and Treatment
|
Dominic Walsh
Dennis Selkoe
|
2012-03-20
|
General Anesthetics and Alzheimer’s Disease
|
Zhongcong Xie
|
2012-03-20
|
Understand the Role of ADAM10 in the Pathogenesis of Alzheimer’s Disease After Head Trauma
|
Giuseppina Tesco
|
2012-03-20
|
Optimization of Novel ACAT Inhibitors for Alzheimer’s Disease
|
Dora M. Kovacs, retired
|
2012-03-20
|
The Development of UDP Analogs for the Treatment of Alzheimer’s Disease
|
Phil Haydon
|
2012-03-20
|
Metallomic Mapping of the Aging Brain in Trg2576 Transgenic Mouse Model
|
Lee Goldstein
|
2012-03-20
|
Cellular and Animal Models of Amyloid Pathology in Early Alzheimer’s Disease
|
Charles Glabe
|
2011-11-11
|
Structural and Functional Analysis of Novel Abeta and Tau Oligomers Using Conformation-Specific Monoclonal Antibodies
|
George S. Bloom
|
2011-11-11
|
Selective Cell Vulnerability in Alzheimer’s Disease
|
Paul Greengard
|
2011-11-11
|
Novel Soluble Gamma-Secretase Modulators for the Treatment of Alzheimer’s Disease Identification of the Molecular Target of Potent Gamma-Secretase Modulators
|
Steven L. Wagner
|
2011-11-11
|
Mechanisms of Retinoid X Receptor-Mediated Abeta Clearance in Alzheimers’ Disease
|
David Holtzman Gary Landreth
|
2011-11-11
|
Effect of Bexarotene on Abeta in APP Tg Mice Expressing ApoE3 and ApoE4
|
David Holtzman Gary Landreth
|
2011-11-11
|
Alzheimer Disease Models Based on Human Neural Progenitor Cells
|
Doo Yeon Kim
|
2011-11-09
|
Exploring Adult Neurogenesis as a Therapeutic Target for Alzheimer’s Disease
|
Se Hoon Choi
|
2011-11-09
|
Molecular Tweezers—Novel Inhibitors of Amyloidogenic Proteins and Promising Drug Candidates for Alzheimer’s Disease
|
Gal Bitan
|
2011-11-09
|
Oligomer Collaborative Projects
|
Charles Glabe David Holtzman Paul Greengard Rudy Tanzi Sam Gandy Sangram S. Sisodia Stephen Strittmatter Tae-Wan Kim Virginia Lee
|
2011-03-01
|
Design, Synthesis and Characterization of Novel and Potent Gamma Secretase Modulators: Physiochemical and Pharmacokinetic Properties
|
Steven L. Wagner
William C. Mobley
|
2011-02-12
|
ADAM10 and Dimebolin
|
Sam Gandy
|
2011-02-12
|
Core Facility for Abeta Microdialysis Drug Discovery Platform
|
David Holtzman
|
2011-02-12
|
Novel Soluable Gamma-Secretase Modulators
|
Steven L. Wagner
Rudy Tanzi
|
2011-02-12
|
Passive Tau Immunotherapy
|
Virginia Lee
|
2011-02-12
|
Three Studies of ACAT Inhibitors as Potential Therapies for AD
|
Dora M. Kovacs, retired
|
2011-02-12
|
Curcumin Collaborative Project
|
Rudy Tanzi William Klunk
|
2011-02-12
|
Peek and Treat Approach to Diagnosis, Treatment and Monitoring of AD
|
Ananth Annapragada Jason Eriksen
|
2011-02-12
|
Support of Cerebrospinal Fluid Biomarker Study–ADNI
|
John Q. Trojanowski Leslie M. Shaw
|
2011-02-12
|
TBI and Stroke Relationship to Alzheimer’s Disease
|
Giuseppina Tesco
|
2011-02-12
|
Development of Tau Microdialysis as a Method to Study Tau Metabolism, Pathophysiology and Response to Treatment
|
David Holtzman
|
2011-02-12
|
Understanding the Up-Regulation of Neuroserpin in the Alzheimer’s Brain and Isolating a Potential Therapeutic Inhibitor of its Action: Continued
|
Nicholas Seeds
|
2011-02-12
|
Longitudinal Study of AD Genotypes
|
Deborah Blacker
|
2011-02-11
|
Relating AD Brain Morphology to AD Genotype
|
Bradley T. Hyman
|
2011-02-11
|
Identification of Agents that Inhibit the Generation and Neurotoxicity of Cross-linked B-amyloid Protein Species
|
Rudy Tanzi
Robert Moir
|
2011-02-11
|
Fine Mapping of Prioritized GWAS Results
|
Lars Bertram
|
2011-02-11
|
Modulation of Abeta Assembly and Cytotoxicity by a Fragment of Myelin Basic Protein
|
William Van Nostrand
|
2011-02-11
|
Molecular Mechanism Underlying Hippocampal Neurogenisis by Familial AD-linked Presenilin-1 Variants
|
Sangram S. Sisodia
|
2011-02-11
|
Investigation of Certain Properties of Mitochondria Membranes Related to AD
|
Rudy Tanzi
Robert Moir
|
2011-02-11
|
Understanding the Cell Biology Underlying the Effects of Abeta on Synapse
|
Roberto Malinow
|
2011-02-11
|
Defining the Effects of Physiological Synaptic Activity on Abeta Levels: Implications for AD
|
David Holtzman
|
2011-02-11
|
miRNAs in AD Pathology
|
Aleister J. Saunders
|
2011-02-11
|
Rescue of Synapses in AD Rodent Models
|
Roberto Malinow
|
2011-02-11
|
Modulation of Abeta Deposition by Cell-Specific Mechanisms
|
Sangram S. Sisodia
|
2011-02-11
|
NMDA Receptors
|
Roberto Malinow
|
2011-02-11
|
Mouse Model for Non-Generic Alzheimer’s Disease
|
Frank LaFerla
|
2011-02-11
|
Anti-APOE Antibodies
|
David Holtzman
|
2011-02-11
|
Brain Structure, Abeta Metabolism and Behavior in Mice Deficient in Diabetes and Alzheimer’s Associated SorCS1
|
Sam Gandy
|
2011-02-11
|
Upkeep and Maintenance of the AlzGene Database
|
Lars Bertram
|
2011-02-11
|
The Amylin Protein of Diabetes Mellitus is an Antimicrobial Peptide
|
Robert Moir
Rudy Tanzi
|
2011-02-11
|